Abstract:Abstract Lung cancer remains one of the most common and deadly diseases worldwide, with a 5-year survival rate of 16%. It is still the leading cause of cancer-associated mortality among both men and women, despite a decreasing incidence rate over the past decade. MicroRNAs (miRNAs), a class of small non-coding RNAs, may regulate the expression of one third of all human genes and are related to carcinogenesis through their function as oncogenes or tumor suppressors. Circulating serum miRNAs that are differentially expressed between early stage lung cancer patients and controls could serve as non-invasive biomarkers for the early detection of lung cancer. In this study, we assessed a total of 89 candidate miRNAs using a quantitative Real-Time PCR method in 200 Caucasian, early stage lung cancer patients (stage I or II disease) and 200 Caucasian healthy controls. We used the rank sum test to assess differential serum miRNA expression levels between cases and controls. Odds ratios [OR] and 95% confidence intervals [CI] were calculated using multivariate logistic regression while adjusting for age, gender and smoking status. Of the 89 candidate miRNAs, 56 miRNAs were expressed in the serum of study subjects and 4 miRNAs (mir409_3p, mir223star, mir152, mir378) exhibited significant differential expression between cases and controls. The most significant association was observed for mir409_3p with a rank-sum test p-value at 0.008. In the stratified analysis, significant association was observed for mir409_3p in younger individuals less than or equal to 65 years of age, mir223star, mir152, and mir378 in older individuals greater than 65 years of age, mir409_3p and mir223star in males, mir152 in females, and mir378 in ever smokers. After dichotomizing serum miRNAs using the 1st quartile cut-off in the controls and comparing to the lowest quartile, we also observed significant associations for mir409_3p, mir223star, mir152, and mir378 with ORs (95% CI) of 0.47 (0.27-0.83), 2.00(1.03-3.88), 0.43(0.25-0.74), and 2.58(1.37-4.86), respectively. Risk score analysis using these 4 miRNAs showed significant increased risk of lung cancer with an increasing risk score (P = 1.64 X 10-6). Under Receiver Operating Characteristic curve analysis, the area under the curve (AUC) for age, gender, and smoking status is 0.76 while AUC increased to 0.81 with the addition of the serum miRNA data. We further downloaded the miRNA expression data from TCGA and found that mir378 and mir152 were available. These two miRNAs exhibited consistent associations (up-regulated for mi378 or down-regulated for mir152) while comparing tumor and normal tissues in lung patients with pathological stage I and II disease and comparing serum in lung cancer cases and controls. In conclusion, serum miRNAs exhibited differential expression between early stage lung cancer cases and controls and could be used for the early detection of lung cancer. Citation Format: Yuanqing Ye, Yan Wang, Jack Roth, Xifeng Wu. Serum MicroRNAs as biomarkers in early stage non-small cell lung cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 298. doi:10.1158/1538-7445.AM2014-298

Tumor-derived exosomal miR-155-5p and miR-658 in serum as diagnostic biomarkers for early-stage non-small cell lung cancer

The diagnostic value of serum exosomal miRNA-587 combined with hypersensitive C-reactive protein as noninvasive biomarker in early-stage non-small cell lung cancer

Circulating miRNAs in Serum as Biomarkers for Early Diagnosis of Non-small Cell Lung Cancer

Identification of Serum Mirnas by Nano-Quantum Dots Microarray As Diagnostic Biomarkers for Early Detection of Non-Small Cell Lung Cancer

Discovery and Validation of Extracellular Vesicle‐associated Mirnas As Noninvasive Detection Biomarkers for Early‐stage Non‐small‐cell Lung Cancer

Accurate Cancer Diagnosis and Stage Monitoring Enabled by Comprehensive Profiling of Different Types of Exosomal Biomarkers: Surface Proteins and Mirnas

Identification of miRNA Biomarkers for Non-small Cell Lung Cancer using Microarray Datasets and Bioinformatics Analysis

Exosomal Let-7D-3p and Mir-30D-5p As Diagnostic Biomarkers for Non-Invasive Screening of Cervical Cancer and Its Precursors

Tumor-derived circulating exosomal miR-342-5p and miR-574-5p as promising diagnostic biomarkers for early-stage Lung Adenocarcinoma

Identification of Ten Serum Micrornas from a Genome‐wide Serum Microrna Expression Profile As Novel Noninvasive Biomarkers for Nonsmall Cell Lung Cancer Diagnosis

Serum exosomal miR ‐1269a serves as a diagnostic marker and plays an oncogenic role in non‐small cell lung cancer

Evaluation of Serum-Paired Mirna Ratios for Early Diagnosis of Non-Small Cell Lung Cancer Using Quantum Dot-Based Suspension Array

Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice

Identification of hsa-miR-619-5p and hsa-miR-4454 in plasma-derived exosomes as a potential biomarker for lung adenocarcinoma.

Abstract 298: Serum MicroRNAs As Biomarkers in Early Stage Non-Small Cell Lung Cancer

Exosomal LncRNA RP5-977B1 as a novel minimally invasive biomarker for diagnosis and prognosis in non-small cell lung cancer

Evaluation of circulating small extracellular vesicle-derived miRNAs as diagnostic biomarkers for differentiating between different pathological types of early lung cancer

Serum microRNA expression profiling revealing potential diagnostic biomarkers for lung adenocarcinoma

Serum exosomal microRNAs combined with alpha-fetoprotein as diagnostic markers of hepatocellular carcinoma.

Tumor‐derived exosomal lncRNA GAS5 as a biomarker for early‐stage non‐small‐cell lung cancer diagnosis

Integrated plasma and exosome long noncoding RNA profiling is promising for diagnosing non-small cell lung cancer